Hostname: page-component-848d4c4894-jbqgn Total loading time: 0 Render date: 2024-06-30T23:27:20.114Z Has data issue: false hasContentIssue false
  • English
  • Français

Aripiprazole once monthly outpatient experience

Published online by Cambridge University Press:  23 March 2020

P. Sánchez Páez ,
J.L. Gómez Cano ,
L. Sánchez Flores ,
R. González Lucas  and
P. Artieda Urrutia
J.L. Gómez Cano
Affiliation:
Hospital Ramón y Cajal, Psychiatry, Madrid, Spain
L. Sánchez Flores
Affiliation:
Hospital Ramón y Cajal, Psychiatry, Madrid, Spain
R. González Lucas
Affiliation:
Hospital Ramón y Cajal, Psychiatry, Madrid, Spain
P. Artieda Urrutia
Affiliation:
Hospital Ramón y Cajal, Psychiatry, Madrid, Spain

Abstract

Introduction

Aripiprazole once monthly (AOM) is one of the most recently introduced antipsychotics with a different mechanism of action, which seems to bring clinical and tolerability implications [1].

Objectives

We describe the patient profile that may benefit from AOM treatment.

Methods

This is a single-centre, retrospective, one year follow-up study of 13 cases of ambulatory AOM use. We analyze clinical and functional evolution, and the tolerability profile of patients in a real clinical practice basis.

Results

Mean age was 53.69; 53.8% were males and 46.2% females. The most frequent diagnosis was Schizophrenia and other chronic psychosis (69.3%). Only 7.7% had co-morbidity with substance use disorder (cocaine); 61.6% were on previous treatment with other injectable anti-psychotics; 84,6% of the sample received AOM as monotherapy. Reasons for switching to AOM are shown on Fig. 1. Events during switching are shown on Fig. 2. Outcomes with AOM long-term treatment were positive in 84.61% of cases and are shown on Fig. 3.

Conclusions

Switching to AOM could be considered as a good strategy to improve tolerability, functionality and ultimately adherence to treatment in patients in middle age of life with a chronic psychotic disorder [2].

Fig. 1

Reasons for switching.

Fig. 2

Events during switching.

Fig. 3

Outcomes with AOM.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
e-Poster Viewing: Psychopharmacology and pharmacoeconomics
Information
European Psychiatry , Volume 41 , Issue S1: Abstract of the 25th European Congress of Psychiatry , April 2017 , pp. S760
Copyright
Copyright © European Psychiatric Association 2017

References

Kane, J, Peters-Strickland, T, Ross, A, et al.Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2014;75(11):1254–126010.4088/JCP.14m09168CrossRefGoogle ScholarPubMed
Fagiolini, A, Brugnoli, R, Di Sciascio, G., et al.Switching antipsychotic medication to aripiprazole: position paper by a panel of Italian psychiatrists. Expert Opin Pharmacother 2015;16(5):727–73710.1517/14656566.2015.1013029CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.